Webinar Part 5: Results of European STAR-II Trial at 6 Months

Show Description +

Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

Up Next

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD


Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO

STAR-GLOBAL 3-Year Results

I. Paul Singh, MD

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD

Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 5: Results of European STAR-II Trial at 6 Months

Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical